Evidence map›Paper›PMID 29995452›Full record

ArticleSLAS discovery : advancing life sciences R & D2018

Development and Characterization of Quantitative, High-Throughput-Compatible Assays for Proteolytic Degradation of Glucagon.

Caitlin N Suire, Shelley Lane, Malcolm A Leissring

Abstract read
In one paragraph

Article in SLAS discovery : advancing life sciences R & D, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Targeting Insulin-Degrading Enzyme in Insulin Clearance.International journal of molecular sciences · 2021
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Caitlin N Suire1 Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Shelley Lane1 Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Malcolm A Leissring1 Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.ORCID 0000-0001-7185-4255

Funding

Zinc-targeting inhibitors of insulin-degrading enzymeR01GM115617 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI LEISSRING, MALCOLM A · 2016 to 2020
$1.4M
Transient defects in Abeta catabolism in the etiology of sporadic Alzheimer diseaseR21AG052718 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI LEISSRING, MALCOLM A · 2017 to 2018
$425k
Peripheral Degradation of Amyloid Beta-ProteinR21AG025070 · NIA · SCRIPPS FLORIDA · PI LEISSRING, MALCOLM A · 2005 to 2006
$332k
NIA NIH HHS R21 AG025070NIA NIH HHS R21 AG052718NIGMS NIH HHS R01 GM115617
6 · The paper itself

Abstract

Glucagon is a vital peptide hormone involved in the regulation of blood sugar under fasting conditions. Although the processes underlying glucagon production and secretion are well understood, far less is known about its degradation, which could conceivably be manipulated pharmacologically for therapeutic benefit. We describe here the development of novel assays for glucagon degradation, based on fluoresceinated and biotinylated glucagon (FBG) labeled at the N- and C-termini, respectively. Proteolysis at any peptide bond within FBG separates the fluorescent label from the biotin tag, which can be quantified in multiple ways. In one method requiring no specialized equipment, intact FBG is separated from the cleaved fluoresceinated fragments using NeutrAvidin agarose beads, and hydrolysis is quantified by fluorescence. In an alternative, high-throughput-compatible method, the degree of hydrolysis is quantified using fluorescence polarization after addition of unmodified avidin. Using a known glucagon protease, we confirm that FBG is cleaved at similar sites as unmodified glucagon and use both methods to quantify the kinetic parameters of FBG degradation. We show further that the fluorescence polarization-based assay performs exceptionally well ( Z'-factor values >0.80) in a high-throughput, mix-and-measure format.

Indexed as

Biological AssayHigh-Throughput Screening AssaysAmino Acid SequenceEnzyme AssaysGlucagonHumansKineticsMass SpectrometryProteolysisGlucagonenzyme assaysenzyme kineticsfluorescence methodsmetabolic diseasesproteaseultra-high-throughput screening

Identifiers

PMID29995452
PMCPMC6585941

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.